Cytotoxicity and radiosensitization effect of TRA-8 on radioresistant human larynx squamous carcinoma cells

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 461-465

  Wu, F ^a   Hu, Y ^a   Long, J ^a   Zhou, Y J ^a   Zhong, Y H ^a   Liao, Z K ^a   Liu, S Q ^b   Zhou, F X ^a   Zhou, Y F ^a   Xie, C H ^a  

^a WUHAN UNIVERSITY   (China)

^b Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center   (China)

Author keywords

Larynx carcinoma; Radioresistant; Radiosensitivity; TRA 8; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; DEATH RECEPTOR 5; MONOCLONAL ANTIBODY TRA 8; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; RADIOSENSITIZING AGENT; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HEP 2 CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IONIZING RADIATION; LARYNX CARCINOMA; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; STAINING; UPREGULATION; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; LARYNX TUMOR; MULTIMODALITY CANCER THERAPY; RADIATION DOSE; RADIATION EXPOSURE; RADIOTHERAPY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LARYNGEAL NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 62849102689     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000245     Document Type: Article

References (42)

1. Britten PA and Evans AJ: Intratumoral heterogeneity as a confounding factor in clonogenic assays for tumor radioreponsiveness. Radiother Oncol 139: 145-153, 1996.
2. Pelevina II, Gotlib VI, Kudriashova OV, Antoshchina MM and Serebrianyi AM: Properties of progeny of irradiated cells. Tsitologiia 40: 467-477, 1998.
3. Luo ZG, Zhou FX, Zhou YF, Xie CH, Dai J and Liu SQ: Radiation-induced radioresistant human squamous carcinoma cell line and its biological characteristics. Zhonghua Fang She Zhong Liu Za Zhi 14: 208-212, 2005.
4. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA and Marsters SA: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
5. Pan G, ORourke K and Chinnaiyan AM: The receptor for the cytotoxic ligand TRAIL. Science 276: 111-131, 1997.
6. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J and Hood L: Death receptor 5, a new member of the TNFR family, and DR4 induced FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7: 821-830, 1997.
7. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY and Boiani N: TRAIL-R2: a novel apoptosismediating receptor for TRAIL. EMBO J 16: 5386-5397, 1997.
8. Marsters SA, Sheridan JP and Pitti RM: Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol 8: 525-530, 1998.
9. Degli-Esposti MA, Smolak PJ and Walczak H: Cloning and characterization of TRAIL-R3 a novel member of the emerging TRAIL receptor family. J Exp Med 186: 1165-1170, 1997.
10. Sheridan JP, Marsters SA and Pitti RM: Control of TRAILinduced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821, 1997.
11. Emery JG, McDonnell P and Burke MB: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273: 14363-14367, 1998.
12. Jo M: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6: 564-567, 2000.
13. Almasan A and Ashkenazi A: Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14: 337-348, 2003.
14. Lawrence D: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383-385, 2001.
15. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D and Ohtsuka T: Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7: 954-960, 2001.
16. Pukac L: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92: 1430-1441, 2005.
17. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ and Zhang S: Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9: 3731-3741, 2003.
18. Straughn JM Jr, Oliver PG, Zhou T, Wang W, Alvarez RD and GrizzleWE: Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 101: 46-54, 2006.
19. Estes JM, Oliver PG, Straughn JM Jr, Zhou T, Wang W and Grizzle WE: Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 105: 291-298, 2007.
20. Zeng Y, Wu XX, Fiscella M, Shimada O, Humphreys R, Albert V and Kakehi Y: Monoclonal antibody to tumor necrosis factorrelated apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 28: 421-430, 2006.
21. Marini P, Denzinger S, Kauder S, Schiller D, Welz S, Jendrossek V, Budach W and Belka C: In vitro and in vivo effects after combined treatment of colorectal tumors with apoptosis inducing trail receptor antibodies HGS-ETR 1 and HGS-ETR2 and radiotherapy. Radiot Oncol 78: S75, 2006.
22. Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D, Stover DR, Dyer MJ and Cohen GM: TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol 139: 568-577, 2007.
23. Attard G, Plummer RE and De Bono JS: Phase 1 and pharmakinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies. Clin Cancer Res 11: S9060, 2005.
24. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H and de Bono J: Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 13: 6187-6194, 2007.
25. Hirte HW, Hotte SJ, Chen EX, et al: HGS-ETR1, a fully human agonistic monoclonal antibody to the tumor necrosis factorrelated apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase 1 trial. Clin Cancer Res 11: S9104, 2005.
26. Mita MT, Tolcher AW and Patnaik A: A phase I, pharmacokinetic (PK) study of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with solid tumors. Proc Am Assoc Cancer Res 46: 544, 2005.
27. Greco FA: Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61: 82-90, 2008.
28. Hamasu T, Inanami O, Asanuma T and Kuwabarb M: Enhanced induction of apoptosis by combined treatment of human carcinoma cells with X rays and death receptor agonists. J Radiat Res 46: 103-110, 2005.
29. Takahashi M, Inanami O, Kubota N, Tsujitani M, Yasui H, Ogura A and Kuwabara M: Enhancement of cell death by TNF alpha-related apoptosis-inducing ligand (TRAIL) in human lung carcinoma A549 cells exposed to x rays under hypoxia. J Radiat Res 48: 461-468, 2007.
30. Kimura K and Gelmann EP: Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. J Biol Chem 275: 8610-8617, 2000.
31. Shankar S, Singh TR and Srivastava RK: Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: intracellular mechanisms. Prostate 61: 35-49, 2004.
32. Shankar S, Singh TR and Chen X: The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol 24: 1133-1140, 2004.
33. Fiveash JB, Gillespie GY, Oliver PG, Zhou T, Belenky ML and Buchsbaum DJ: Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys 71: 507-516, 2008.
34. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R and Zhou T: Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22: 2034-2044, 2003.
35. Long JW, Derosier LC, Vickers SM, Sellers J, Wang W, Arnoletti JP and Buchsbaum DJ: TRA-8 (TRAIL-R2 antibody) based combination chemotherapy produces a survival benefit in a pancreatic cancer orthotopic model. J Surg Res 137: 167, 2007.
36. Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W and Buchsbaum DJ: Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res 14: 2180-2189, 2008.
37. Kendrick JE, Straughn JM Jr, Oliver PG, Wang W, Nan L, Grizzle WE, Stockard CR, Alvarez RD and Buchsbaum DJ: Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol Oncol 108: 591-597, 2008.
38. Long JW, Buchsbaum DJ, Sellers J, Huang Z, Vickers SM and Arnoletti P: Erlotinib reduces flip mediated resistance to TRA-8 agonistic TRAIL-R2 antibody in pancreatic cancer cells. J Surg Res 144: 387-388, 2008.
39. Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L and Kurzrock R: Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther 5: 2991-3000, 2006.
40. Tartaglia LA and Goeddel DV: Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor. J Biol Chem 267: 4304-4307, 1992.
41. Havell EA, Fiers W and North RJ: The antitumor function of tumor necrosis factor (TNF) I Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 167: 1067-1085, 1988.
42. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T and Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809, 1993.